Unique Effect of Nebivolol on Coronary Hemodynamics: It’s All a Matter of Flow Eli I. LevAlexander Battler Editorial 07 April 2007 Pages: 75 - 76
Cerebrovascular Events After Discontinuation of Rofecoxib Treatment Frank Andersohn Editorial 03 April 2007 Pages: 77 - 79
Statin Pleiotropy: A Popular Concept but Clinical Significance Unclear Jennifer G. RobinsonHelmut Schrott Editorial 07 April 2007 Pages: 81 - 83
Effect of β-Blockers on β3-Adrenoceptor Expression in Chronic Heart Failure Qiang ZhaoTong-Guo WuLe-Xin Wang OriginalPaper 18 April 2007 Pages: 85 - 90
The Effect of Aggressive Versus Conventional Lipid-lowering Therapy on Markers of Inflammatory and Oxidative Stress Douwe J. MulderPaul L. van HaelstJasper J. van Doormaal OriginalPaper Open access 07 March 2007 Pages: 91 - 97
Does the β-Blocker Nebivolol Increase Coronary Flow Reserve? Mario TogniFrancesco VigoritoOtto M. Hess Clinical Pharmacology and Drug Studies 26 January 2007 Pages: 99 - 108
Inverse Relationship between Lipid-lowering Drugs and Saturated Fat Intake in US Adults Devin M. MannSundar Natarajan OriginalPaper 20 March 2007 Pages: 109 - 115
Long-term Risk of Ischemic Stroke Associated with Rofecoxib Jonathan AfilaloMichael J. Coussa-CharleyMark J. Eisenberg ReviewPaper 28 March 2007 Pages: 117 - 120
Pharmacogenomics of Renin Angiotensin System Inhibitors in Coronary Artery Disease James P. TsikourisMichael J. Peeters Review 08 May 2007 Pages: 121 - 132
Advertising Campaigns of Sterol-Enriched Food. An Often Neglected Cause of Reduced Compliance to Lipid Lowering Drug Therapy Alevizos AlevizosConstantinos MihasAnargiros Mariolis Letter to the Editor 15 March 2007 Pages: 133 - 134
